COVID-19 and the U.S.–Japan Trade Agreement, Phase 2

COVID-19 has inspired doctors and scientists to collaborate around the world in pursuit of a vaccine. Trade policy needs to help, not hurt, these efforts. The next phase of the U.S.–Japan trade agreement should show the way.

The medical response to COVID-19 has been amazing. The time from RNA sequencing of COVID-19 to clinical trials of a vaccine was a mere 65 days, not the several years it took for SARS. Doctors and scientists talk about the need to respond to COVID-19 by learning and even sharing across borders.

In contrast, a lot of the trade talk to date has centered on the need to re-shore medical supply chains around the world (i.e. bring them back home). COVID-19 has led countries to misguidedly impose import and export restrictions on items ranging from soap to masks.

Get latest news delivered daily!

We will send you breaking news right to your inbox

© 2025 GovernmentExclusive.com, Privacy Policy